0.5 mg ranibizumab
Sponsors
Quark Pharmaceuticals, New England Retina Associates, Charles C Wykoff, PhD, MD, Greater Houston Retina Research, King's College Hospital NHS Trust
Conditions
Age Related Macular DegenerationChoroidal MelanomaMacular DegenerationNeovascular (Wet) Age-related Macular Degeneration (AMD)Neovascular Age-related Macular DegenerationRadiation Retinopathy
Phase 2
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
CompletedNCT00713518
Start: 2009-11-30End: 2011-07-31Updated: 2012-10-12
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
CompletedNCT01251978
Start: 2010-07-31End: 2012-08-31Updated: 2016-10-19
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
CompletedNCT02222610
Start: 2014-09-23End: 2019-03-31Updated: 2021-03-25
Phase 3
Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
CompletedNCT01748292
Start: 2012-12-31End: 2017-02-28Updated: 2019-06-04
Stereotactic Radiotherapy for Wet AMD (STAR)
CompletedNCT02243878
Start: 2014-12-31End: 2024-04-30Target: 411Updated: 2025-08-06
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
TerminatedNCT04757610
Start: 2021-03-12End: 2025-03-31Updated: 2025-07-22